MetaCap

Pulmonx (LUNG) vs Neuronetics (STIM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pulmonx (LUNG) has outperformed Neuronetics (STIM) over the past year, gaining 78.5% versus a loss of 4.6%. Over five years, STIM leads with a -69.7% price change compared with -92.4% for LUNG. Neuronetics is the larger company by market cap ($120.6 million vs $111.9 million), about 1.1 times the size.

Neuronetics converts more of its revenue into profit, with a net margin of -26.1% versus -59.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LUNG+78.47%STIM-4.58%
+160%+67%-27%
Nov 21, 20251 yearNov 20, 2026
LUNG-92.59%STIM-68.75%
+80%-12%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LUNG versus STIM key metrics
MetricLUNGSTIM
Share price$2.57$1.25
Market cap$111.93M$120.60M
1-day change-6.20%+0.81%
YTD return+16.29%-9.42%
1-year return+78.47%-4.58%
5-year return-92.39%-69.66%
EPS (TTM)$-1.01$-0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$90.50M$149.16M
Revenue growth (YoY)+8.01%+99.17%
Net income (latest FY)$-54.00M$-39.00M
Gross margin74.19%48.48%
Operating margin-59.30%-21.08%
Net margin-59.67%-26.15%
52-week high$3.25$3.44
52-week low$1.13$0.80
Distance from 52-week high-20.92%-63.66%
Analyst consensusnonestrong_buy
Avg. price target upside+65.37%+380.00%
Average volume641.52K1.76M
Shares outstanding43.55M96.48M
Employees296658
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LUNG has outperformed STIM by 83.1 percentage points over the past year.
  • Neuronetics is more profitable, keeping -26.1 cents of every revenue dollar as net income versus -59.7 cents for Pulmonx.
  • Neuronetics grew revenue faster in its latest fiscal year (+99.17% vs +8.01%).

About Pulmonx

LUNG stock →

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Health Care · Medical/Dental Instruments · 296 employees

About Neuronetics

STIM stock →

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.

Health Care · Medical/Dental Instruments · 658 employees

LUNG vs STIM FAQ

Which is bigger, Pulmonx or Neuronetics?

Neuronetics (STIM) is larger, with a market capitalization of $120.60M compared with $111.93M for Pulmonx (LUNG).

Which stock has performed better over the past year, LUNG or STIM?

LUNG returned +78.47% over the past 12 months, compared with -4.58% for STIM (price return, excluding dividends). Past performance does not predict future results.

Are Pulmonx and Neuronetics in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons